Quest for Ideal Composite Biomarkers for Response to Immunotherapies
- PMID: 32759359
- DOI: 10.1158/1078-0432.CCR-20-2321
Quest for Ideal Composite Biomarkers for Response to Immunotherapies
Abstract
In the CheckMate 275 study, composite biomarkers appear to better predict response to immunotherapy over individual ones. Nevertheless, the path forward needs consensus guidelines for biomarker interpretation. Thereafter, prospective validation with real-time, serial biospecimen collection along with the development of composite biomarker models leads to the goal of personalized therapy.See related article by Galsky et al., p. 5120.
©2020 American Association for Cancer Research.
Comment on
-
Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275.Clin Cancer Res. 2020 Oct 1;26(19):5120-5128. doi: 10.1158/1078-0432.CCR-19-4162. Epub 2020 Jun 12. Clin Cancer Res. 2020. PMID: 32532789 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
